– USA, CA – Ansa Biotechnologies, a pioneer of next-generation DNA synthesis, today announced the appointment of Dr. Matt McManus (M.D, Ph.D.) to its Board as Independent Director and Board Chair.
“We’re thrilled to welcome Matt to the Board as we enter our next stage of growth. His extensive life sciences products and services commercialization expertise will be invaluable as we bring our long-write DNA synthesis technology to market,” said CEO & Co-Founder, Daniel Lin-Arlow.
About Dr. Matthew F. McManus
Dr. McManus brings decades of experience in the life sciences industry to the Board. He was most recently EVP and COO at Azenta (NASDAQ: AZTA), a global life sciences tools, products, and services company. Before Azenta, Dr. McManus was SVP and GM of the Molecular Diagnostics Division at Bio-Techne following its acquisition of Asuragen, where he served as President and CEO and led the strategic transformation of the business into a profitable global molecular diagnostics company. Previously, Dr. McManus was the President and CEO of PrimeraDx, a company that developed and commercialized a novel molecular diagnostics instrument platform and was acquired by Qiagen.
“Ansa’s proprietary DNA synthesis technology will power future innovations in medicine, agriculture, industrial biology, and other applications,” said Dr. Matt McManus. “I am honored to have the opportunity to work with the Ansa Bio team to help realize this potential.”
Dr. McManus received his M.D. and Ph.D. from the University of Pennsylvania, his MBA from Boston College, and his B.A. in Economics from the College of the Holy Cross.
About Ansa Biotechnologies
Ansa Biotechnologies is building a fast and reliable DNA synthesis service to accelerate synthetic biology research. Our core technology is a novel DNA synthesis method based on enzymes that are faster, cleaner, and more accurate than existing methods.
For more information: https://ansabio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.